Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination (ResisTec)

Toulouse University Hospital

Status: Not yet enrolling

Conditions: Multiple Myeloma

Treatments: Other: Bone marrow sampling

Study type: Interventional

Funder types: Other

Identifiers

NCT05945524

RC31/23/0278

Details and patient eligibility

About

The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• With multiple myeloma
• Who receive Teclistamab
• Consent form signed

Exclusion criteria

• Patient under legal protection

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Analysis of bone marrow

Experimental group

Description:

Analysis of bone marrow in patients initiated treatment by Teclistamab for 18 cycles

Treatment:

Other: Bone marrow sampling